Pusztai Lajos, Cristofanilli Massimo, Paik Soonmyung
Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston, TX 77230-1439, USA.
Semin Oncol. 2007 Apr;34(2 Suppl 3):S10-6. doi: 10.1053/j.seminoncol.2007.03.015.
Breast cancer is a clinically heterogeneous disease, and it is generally accepted that the different clinical courses of patients with histologically similar tumors are due to molecular differences among cancers. Therefore, detailed molecular analysis of the cancer could yield prognostic information. Recent advances in molecular analytical techniques have led to rapid expansion of novel diagnostics designed to personalize breast cancer care. Diagnostic companies are also increasingly adopting a clinical trial-based approach to develop their products. This article reviews some of the most important advances in this field in the past few years, including the emergence of several multigene and prognostic predictors, as well as methods allowing enumeration of circulating tumor cells that are currently offered as commercially available diagnostic assays.
乳腺癌是一种临床异质性疾病，人们普遍认为，组织学上相似的肿瘤患者具有不同的临床病程是由于癌症之间的分子差异所致。因此，对癌症进行详细的分子分析可以产生预后信息。分子分析技术的最新进展导致了旨在实现乳腺癌个性化治疗的新型诊断方法迅速增加。诊断公司也越来越多地采用基于临床试验的方法来开发其产品。本文回顾了过去几年该领域的一些最重要进展，包括几种多基因和预后预测指标的出现，以及目前作为商业诊断检测方法提供的循环肿瘤细胞计数方法。
